Apellis Pharmaceuticals Inc (APLS)
30.77
+3.02
(+10.88%)
USD |
NASDAQ |
Nov 22, 16:00
30.76
-0.01
(-0.03%)
After-Hours: 20:00
Apellis Pharmaceuticals Cash from Financing (Quarterly): 2.542M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.542M |
| June 30, 2024 | 42.49M |
| March 31, 2024 | 108.21M |
| December 31, 2023 | -3.913M |
| September 30, 2023 | 5.746M |
| June 30, 2023 | 1.56M |
| March 31, 2023 | 391.11M |
| December 31, 2022 | -15.95M |
| September 30, 2022 | 9.636M |
| June 30, 2022 | -4.735M |
| March 31, 2022 | 376.70M |
| December 31, 2021 | 383.96M |
| September 30, 2021 | 2.12M |
| June 30, 2021 | 4.526M |
| March 31, 2021 | 1.632M |
| Date | Value |
|---|---|
| December 31, 2020 | 6.317M |
| September 30, 2020 | 0.926M |
| June 30, 2020 | 281.67M |
| March 31, 2020 | 403.27M |
| December 31, 2019 | 0.209M |
| September 30, 2019 | 198.95M |
| June 30, 2019 | 40.96M |
| March 31, 2019 | 148.42M |
| December 31, 2018 | 0.1153M |
| September 30, 2018 | -0.0384M |
| June 30, 2018 | 131.60M |
| March 31, 2018 | 0.2227M |
| December 31, 2017 | 178.04M |
| September 30, 2017 | 19.33M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-15.95M
Minimum
Dec 2022
403.27M
Maximum
Mar 2020
99.90M
Average
5.136M
Median
Cash from Financing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -499.12M |
| Ionis Pharmaceuticals Inc | 496.05M |
| EyePoint Pharmaceuticals Inc | 11.89M |
| Cassava Sciences Inc | 0.00 |
| Macrogenics Inc | -0.068M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 34.10M |
| Free Cash Flow | -205.58M |
| Free Cash Flow Per Share (Quarterly) | 0.2745 |
| Free Cash Flow to Equity (Quarterly) | 39.06M |
| Free Cash Flow to Firm (Quarterly) | 43.84M |
| Free Cash Flow Yield | -5.43% |